Pfizer omicron vaccine: Company begins studying updated shot to match variant

  • 📰 FOX4
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

Business News News

Business Business Latest News,Business Business Headlines

Pfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant.

An advisory panel of the World Health Organization classified on Nov. 27, 2021, a worrying new COVID-19 variant first detected in South Africa as a highly transmissible virus of concern, naming it "Omicron" under its Greek letter system.

While omicron is more likely than previous variants to cause infection even in people who’ve been vaccinated, it’s not yet clear that a change to the vaccine recipe is needed.The original vaccines still offer good protection against severe illness and death. Studies in the U.S. and elsewhere have made clear that adding a booster dose strengthens that protection and improves the chances of avoiding a milder infection.

The new U.S. study is enrolling up to 1,420 healthy adults, ages 18 to 55, to test the updated omicron-based shots for use as a booster or for primary vaccinations. Researchers will examine the tweaked vaccine’s safety and how it revs up the immune system in comparison to the original shots.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 289. in BUSİNESS

Business Business Latest News, Business Business Headlines